Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK- Anaplastic Large Cell Lymphoma (ALCL)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03703050
What this trial is testing

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

Who this might be right for
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
Gustave Roussy, Cancer Campus, Grand Paris 45
Post-approval studies (Phase 4)UnknownNCT03707847
What this trial is testing

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Who this might be right for
ALK-Positive Anaplastic Large Cell Lymphoma
Mingzhi Zhang 20
Early research (Phase 1)Study completedNCT01742286
What this trial is testing

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
ALK-activated Tumors
Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Study completedNCT01035463
What this trial is testing

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeRecurrent Anaplastic Large Cell LymphomaRecurrent Mantle Cell Lymphoma+3 more
University of Nebraska 74
Testing effectiveness (Phase 2)Study completedNCT03493451
What this trial is testing

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Who this might be right for
Peripheral T Cell LymphomaPTCLExtranodal NK/T-cell Lymphoma+16 more
BeiGene 77
Testing effectiveness (Phase 2)Study completedNCT01524926
What this trial is testing

CREATE: Cross-tumoral Phase 2 With Crizotinib

Who this might be right for
Locally Advanced and/or Metastatic Anaplastic Large Cell LymphomaLocally Advanced and/or Metastatic Inflammatory Myofibroblastic TumorLocally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1+3 more
European Organisation for Research and Treatment of Cancer - EORTC 582
Testing effectiveness (Phase 2)Active Not RecruitingNCT02978625
What this trial is testing

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine Carcinoma+36 more
National Cancer Institute (NCI) 68
Not applicableStudy completedNCT01366170
What this trial is testing

Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma

Who this might be right for
Lymphoma
Children's Oncology Group 7
Testing effectiveness (Phase 2)Ended earlyNCT03075553
What this trial is testing

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmHepatosplenic T-Cell LymphomaHTLV-1 Infection+14 more
Mayo Clinic 12
Testing effectiveness (Phase 2)UnknownNCT04796857
What this trial is testing

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Who this might be right for
Non-GCB/ABC Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 30
Early research (Phase 1)Not Yet RecruitingNCT07729397
What this trial is testing

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)Hodgkin LymphomaPeripheral T-cell Lymphoma (PTCL)+2 more
The Methodist Hospital Research Institute 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07535762
What this trial is testing

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Who this might be right for
Peripheral T-Cell Lymphoma (PTCL NOS)Nodal T-follicular Helper Cell LymphomaAnaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
Shanghai Jiao Tong University School of Medicine 36
Large-scale testing (Phase 3)Looking for participantsNCT05770037
What this trial is testing

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+8 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Ended earlyNCT02462538
What this trial is testing

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Who this might be right for
ALK+ Anaplastic Large Cell Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 3
Testing effectiveness (Phase 2)Ended earlyNCT00082017
What this trial is testing

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

Who this might be right for
Lymphoma, Large-Cell, Ki-1Lymphoma, T-Cell
National Cancer Institute (NCI) 20
Large-scale testing (Phase 3)Looking for participantsNCT06724237
What this trial is testing

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeFollicular Helper T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type+1 more
Eastern Cooperative Oncology Group
Testing effectiveness (Phase 2)UnknownNCT01719835
What this trial is testing

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Who this might be right for
Peripheral T-cell Lymphoma NOSAnaplastic Large Cell Lymphoma, ALK-NegativeAngioimmunoblastic T-cell Lymphoma+2 more
Royal Marsden NHS Foundation Trust 87
Not applicableStudy completedNCT03040206
What this trial is testing

Risk Stratification of Nodal PTCL

Who this might be right for
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaAnaplastic Large Cell Lymphoma, ALK-negative
Chonbuk National University Hospital 405
Post-approval studies (Phase 4)WithdrawnNCT02487316
What this trial is testing

Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Who this might be right for
Systemic Anaplastic Large-Cell Lymphoma
Jun Zhu
Testing effectiveness (Phase 2)Study completedNCT03505554
What this trial is testing

Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
University of Milano Bicocca 9
Next Page
294